Program
ACC017
A development code. Also written as “ACC017+FTC/TAF” and “ACC017 tablets”.
Its studies are mostly in Infections, led by Jiangsu Aidea Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Group | 42 open or running | phase 2since Nov 26, 2024 | Jan 23, 2024 | Jun 30, 2027phase 2 · NCT07711210 |
Also a collaborator on its studies: chengdu-aidea-pharmaceutical-technology-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2024First study: phase 1 study in Healthy Adult ParticipantsFirst studyNCT06278389 · 48 enrolled · China
- Nov 26, 2024Phase 2 study in InfectionsNCT06719310 · 36 enrolled · China
- Jul 7, 20262 phase 2 studies in InfectionsNCT07711223, NCT07711210
Ahead
- Jun 30, 2027Primary completion: phase 2 study in InfectionsNCT07711210
- Aug 31, 2028Primary completion: phase 2 study in InfectionsNCT07711223
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07711223Infections · China | 2 | Recruiting | Aug 31, 2028 | 660 |
| NCT07711210Infections · China | 2 | Active, not recruiting | Jun 30, 2027 | 12 |
| NCT06719310Infections · China | 2 | Completed | Apr 28, 2025 | 36 |
| NCT06278389Healthy Adult Participants · China | 1 | Completed | May 20, 2024 | 48 |
How it is read
Names in the registry
- “ACC017+FTC/TAF”, 2 entries
- “ACC017 tablets”, 1 entry
- “ACC017”, 1 entry
Codes read as this program: ACC017.
Conditions, from the studies’ own filings
- Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.